PTR-01 clinical trials
Also written PTR-01.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses PTR-01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PTR-01
- 3
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses PTR-01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)CompletedPhase 2Phoenix Tissue Repair, Inc.NCT05143190Written as PTR-01
- A Study of PTR-01 in Recessive Dystrophic Epidermolysis BullosaCompletedPhase 2Phoenix Tissue Repair, Inc.NCT04599881Written as PTR-01
- A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)CompletedPhase 1/2Phoenix Tissue Repair, Inc.NCT03752905Written as PTR-01